Acute Renal Failure (ARF) (Acute Kidney Injury) – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Acute Renal Failure (ARF) (Acute Kidney Injury) – Drugs In Development, 2023’, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury)
- The report reviews pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics and enlists all their major and minor projects
- The report assesses Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury)
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Akebia Therapeutics IncAlexion Pharmaceuticals Inc
Alloksys Life Sciences BV
Amniotics AB
Anagenics Ltd
Angiotensin Therapeutics Inc
AptaBio Therapeutics Inc
Arch Biopartners Inc
Arizona State University
Atorvia Health Technologies LLC
Axolo Pharma Inc
Balmes Transplantation SAS
Bessor Pharma LLC
CalciMedica Inc
CAMP Therapeutics Inc
CFM Pharma Holding BV
Changchun GeneScience Pharmaceutical Co Ltd
Chaperone Pharma BV
Claritas Pharmaceuticals Inc
CSPC Pharmaceutical Group Ltd
Cypralis Ltd
DeckTherapeutics Inc
DURECT Corp
Elicio Therapeutics Inc
Evotec SE
Exponential Biotherapies Inc
F. Hoffmann-La Roche Ltd
Function Therapeutics Inc
Goldilocks Therapeutics Inc
Haisco Pharmaceutical Group Co Ltd
HemaFlo Therapeutics Inc
Hybridize Pharma BV
iCELL Biotechnology Co Ltd
ILIAS Biologics Inc
Johnson & Johnson
Kantum Pharma Inc
Keli Therapeutics
Klotho Therapeutics Inc
Kringle Pharma Inc
LTT Bio-Pharma Co Ltd
MabTics
Marshall University
Meridigen Biotech Co Ltd
Metro International Biotech LLC
Mission Therapeutics Ltd
Mitotech SA
Mitotherapeutix LLC
Nephraegis Therapeutics
Novartis AG
Orgenesis Inc
Paranta Biosciences Ltd
Paxmedica Inc
Pharmazz Inc
Pharmicell Co Ltd
Praetego Inc
Q BioMed Inc
Radikal Therapeutics Inc
RedHill Biopharma Ltd
Redx Pharma Plc
Renibus Therapeutics Inc
Revelation Biosciences Inc
River 2 Renal Corp
Rui Nuo Medical Technology (Shanghai) Co Ltd
SeaBeLife Spas
Secretome Therapeutics
Sentien Biotechnologies Inc
Serpin Pharma LLC
Sidereal Therapeutics Inc
Silver Creek Pharmaceuticals Inc
Slate Bio Inc
STATegics Inc
Sulfateq BV
TES Pharma SRL
TheraSource LLC
Theratome Bio Inc
TMS Co Ltd
TNAX Biopharma Corp
Unicycive Therapeutics Inc
Unicyte AG
University of Pittsburgh
Valo Health LLC
Vasculonics LLC
Vasomune Therapeutics Inc
Verinos Pharmaceuticals GmbH
Verra Therapeutics LLC
Vivoryon Therapeutics NV
XORTX Therapeutics Inc
Yale University